These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
514 related articles for article (PubMed ID: 29126911)
21. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer. Barnett BS; Greer GR J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406 [TBL] [Abstract][Full Text] [Related]
22. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Bouso JC; Doblin R; Farré M; Alcázar MA; Gómez-Jarabo G J Psychoactive Drugs; 2008 Sep; 40(3):225-36. PubMed ID: 19004414 [TBL] [Abstract][Full Text] [Related]
27. Psychedelic drugs for psychiatric disorders. da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696 [TBL] [Abstract][Full Text] [Related]
28. Dosing Psychedelics and MDMA. Liechti ME; Holze F Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392 [TBL] [Abstract][Full Text] [Related]
29. The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD. Brewerton TD; Lafrance A; Mithoefer MC Med Hypotheses; 2021 Jan; 146():110367. PubMed ID: 33203569 [TBL] [Abstract][Full Text] [Related]
30. Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. Fogg C; Michaels TI; de la Salle S; Jahn ZW; Williams MT Exp Clin Psychopharmacol; 2021 Oct; 29(5):539-554. PubMed ID: 34096755 [TBL] [Abstract][Full Text] [Related]
31. Can drugs be used to enhance the psychotherapeutic process? Grinspoon L; Bakalar JB Am J Psychother; 1986 Jul; 40(3):393-404. PubMed ID: 2876654 [TBL] [Abstract][Full Text] [Related]
33. Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine-Assisted Therapy for Posttraumatic Stress Disorder: A Review of the Evidence, Neurobiological Plausibility, and Clinical Significance. Price CM; Feduccia AA; DeBonis K J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):464-469. PubMed ID: 36018231 [TBL] [Abstract][Full Text] [Related]
34. Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. Dunlap LE; Andrews AM; Olson DE ACS Chem Neurosci; 2018 Oct; 9(10):2408-2427. PubMed ID: 30001118 [TBL] [Abstract][Full Text] [Related]
35. Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine. Fattore L; Piva A; Zanda MT; Fumagalli G; Chiamulera C Psychopharmacology (Berl); 2018 Feb; 235(2):433-445. PubMed ID: 29178010 [TBL] [Abstract][Full Text] [Related]
36. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. Barnett BS; Parker SE; Weleff J Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734 [TBL] [Abstract][Full Text] [Related]
37. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Majić T; Schmidt TT; Gallinat J J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401 [TBL] [Abstract][Full Text] [Related]
39. The emerging role of psilocybin and MDMA in the treatment of mental illness. Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860 [TBL] [Abstract][Full Text] [Related]
40. MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics". Sessa B Neurosci Lett; 2017 May; 649():176-180. PubMed ID: 27394687 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]